Oxford Immunotec Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2016 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions, today announced that it plans to
release second quarter 2016 financial results prior to market open on Tuesday,
August 2, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick
Altieri, Chief Financial Officer, will host a conference call to review the
Company's results at 8:00 a.m. Eastern Time the same day. The call will be
concurrently webcast.
To listen to the conference call on your telephone, please dial (855) 363-5047
for United States callers and +1 (484) 365-2897 for international callers and
reference confirmation code 47066686, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec's website
at www.oxfordimmunotec.com. The replay will be available on the Company's
website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
immune-regulated conditions. The Company's first product is the T-
SPOT(®).TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and
third products and part of a series of products intended for the transplantation
market. In addition to these three products, the Company has an additional six
active development programs, each of which leverages our T cell, B cell and
innate immune measuring technology. The Company is headquartered near Oxford,
U.K. and in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec(at)westwicke.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
[HUG#2029216]
Unternehmensinformation / Kurzprofil:
Datum: 18.07.2016 - 18:08 Uhr
Sprache: Deutsch
News-ID 483843
Anzahl Zeichen: 3475
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
